Format

Send to

Choose Destination
Leuk Lymphoma. 2019 Jul;60(7):1626-1631. doi: 10.1080/10428194.2019.1594220. Epub 2019 Apr 18.

Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation.

Author information

1
a Department of Medicine , Weill Cornell Medicine/New York Presbyterian Hospital , New York , NY , USA.
2
b Department of Pathology and Laboratory Medicine , Weill Cornell Medicine/New York Presbyterian Hospital , New York , NY , USA.
3
c Memorial Sloan Kettering Cancer Center , New York , NY , USA.

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center